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Nur77/NR4A1 is an “orphan member” of the nuclear
hormone receptor superfamily. Nur77 and its close rela-
tives Nurr1 and NOR-1 bind as monomers to a consensus
binding site, the nerve growth factor induced protein I-B
(NGFI-B)-binding response element (NBRE). The Nur77/
NURR1/NOR1 nuclear receptors are classified as immedi-
ate early response genes which are induced through mul-
tiple signal transduction pathways. They have been
implicated in cell proliferation, differentiation, and apo-
ptosis. However, the mechanism of coactivation and li-
gand independent trans-activation remains unclear.
Hence we examined the molecular basis of Nur77-medi-
ated cofactor recruitment and activation. We observed
that Nur77 trans-activates gene expression in a cell-spe-
cific manner, and operates in an activation function-1
(AF-1)-dependent manner. The AB region encodes an un-
commonly potent N-terminal AF-1 domain delimited to
between amino acids 50 and 160 and is essential for the
ligand-independent activation of gene expression. Steroid
receptor coactivator-2 (SRC-2) modulates the activity of
the N-terminal AF-1 domain. Moreover, SRC-2 dramati-
cally potentiates the retinoid induced RXR-dependent
activation of the Nur77 ligand binding domain (LBD).
Interestingly, the N-terminal AB region (not the LBD)
facilitates coactivator recruitment and directly inter-
acts with SRC, p300, PCAF, and DRIP-205. Consistent
with this, homology modeling indicated that the Nur77
LBD coactivator binding cleft was substantially differ-
ent from that of retinoic acid receptor , a closely re-
lated AF-2-dependent receptor. In particular, the hydro-
phobic cleft characteristic of nuclear receptors was
replaced with a much more hydrophilic surface with a
distinct topology. This observation accounts for the in-
ability of this nuclear receptor LBD to directly mediate
cofactor recruitment. Furthermore, the AF-1 domain
physically associates with the Nur77 C-terminal LBD
and synergizes with the retinoid X receptor LBD. Thus,
the AF-1 domain plays a major role in Nur77-mediated
transcriptional activation, cofactor recruitment, and in-
tra- and intermolecular interactions.
Nuclear hormone receptors (NRs)1 function as ligand-acti-
vated transcription factors that regulate gene expression in-
volved in reproduction, development, and general metabolism
(1). NRs function as the conduit between physiology and gene
expression. The importance of NRs in human physiology is
underscored by the extensive pharmacopoeia that has been
created to combat disorders associated with dysfunctional hor-
mone signaling. These diseases affect every discipline of med-
icine (2). All members of the NR superfamily display a highly
conserved structural organization (1) with an N-terminal re-
gion AB (which encodes activation function-1, AF-1) followed
by the C-region (which encodes the DNA binding domain
(DBD)), a linker region D, and the C-terminal E region. The DE
region encodes the ligand binding domain (LBD) and a tran-
scriptional domain, denoted as activation function-2 (AF-2)
(1, 2).
A decade ago, gene products were identified which appeared
to belong to the NR superfamily on the basis of their nucleic
acid sequence identity. The endogenous signaling molecules
that bound to these proteins were unknown, and thus the term
“orphan receptor” was coined. Based on members of the NR
superfamily which have been characterized more fully, the
orphans forecast an enormous yet unexploited opportunity for
the discovery of important new therapeutic agents. The poten-
tial impact of such a discovery cannot be overstated because
every known NR has been implicated in human disease.
The Nur77, Nurr1, and NOR-1 (NR4A1–3 subgroup) family
of orphan NRs is well conserved in the DBD (91–95%) and the
C-terminal LBD (60%), but it is divergent in the N-terminal
AB region. This subgroup of proteins functions as immediate-
early response genes that are induced by a wide range of
physiological signals (3–7). They have been implicated in pro-
liferation, differentiation, apoptosis, hypertrophy/remodeling,
Parkinson’s disease, schizophrenia, manic depression, and au-
toimmune disease (8–19). In itself, the NR4A1–3 subgroup
presents an exciting scientific challenge, and unlocking the
molecular mechanisms that mediate NR4A-dependent tran-
scription will provide a potential platform for pharmacological
intervention.
Nur77 has been shown to play a key role in regulating
expression of various genes in the hypothalamic-pituitary-ad-
renal axis (HPA) related to inflammation and steroidogenesis
(20–22). Specifically, Nur77 family members activate expres-
sion of corticotropin-releasing hormone (19). The Nur77 family
can regulate steroid 21-hydroxylase, steroid 17-hydroxylase,
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and the 20-hydroxysteroid dehydrogenase promoters (21–22).
As such, the NR4A family of proteins represents a potential
target for therapeutic intervention to control inflammatory
responses.
Nur77 is expressed in skeletal muscle (23) and mouse myo-
blasts in culture (24, 26–27). Moreover, basic fibroblast growth
factor, 12-O-tetradecanoylphorbol-13-acetate, and forskolin
agonists induce Nur77 expression in mouse myoblasts. Early
studies demonstrated that Nur77 expression in muscle ap-
peared to be dependent to different extents on the activation of
protein kinase A, C, and mitogen-activated protein kinase. -Ad-
renergic agonists transiently induce Nur77 in mouse myoblasts
(24, 26–27). Chronic stimulation of muscle with adrenergic
agonists induces hypertrophy, fast type II fibers, and muscle
remodeling, and it reduces skeletal muscle wasting (25).
The NR4A family members can bind as monomers and as
homodimers to single/tandem copies of the NR4A response
element, AAAGGTCA, a variant NR half-site, and constitu-
tively regulate transcription (28–30). Moreover, Nur77 and
Nurr1 (but not NOR-1) heterodimerize with RXR and mediate
efficient trans-activation in response to RXR-specific agonists
from DR5 motifs (31–33). The NR4A subgroup functions as
immediate-early response genes, which suggests cross-talk be-
tween multiple classes of stimuli and retinoid-dependent sig-
naling. Moreover, phosphorylation of Nur77 regulates retinoid
signaling by controlling the subcellular localization and nucleo-
cytoplasmic shuttling of RXR (7). In addition, serine and thre-
onine residues in Nur77 have been demonstrated to be critical
in the activity, function, and localization of the NR4A members
(5, 7, 34, 35).
This receptor subgroup has proven to be refractory to the
understanding of coactivator recruitment in the process of con-
stitutive trans-activation and retinoid-induced RXR-dependent
regulation (31–33). Moreover, the Nur77 LBD lacks an intrin-
sic and classical activation domain, and the serine/threonine-
rich domain in the N terminus has been implicated in the
regulation of Nur77-dependent transcription (36). Further-
more, the N-terminal AB region has been implicated in growth
factor-dependent nucleo-cytoplasmic shuttling of this NR (7).
In summary, the N-terminal AF-1 region, the C-terminal
LBD, and AF-2 domain of the Nur77 subgroup are very un-
usual. Nur77 lacks an archetypal AF-2 transcriptional activa-
tion domain and does not seem to interact with NR cofactors;
notwithstanding these comments, this orphan modulates tran-
scription. Currently, the molecular aspects of transcriptional
activation remain obscure; furthermore, structural analysis of
the LBD and mechanistic analysis of Nur77 function have not
been undertaken with respect to intramolecular interactions
and cofactor recruitment.
We have demonstrated and analyzed the functional role of
AF-1 in mouse NR4A1 (Nur77)-mediated trans-activation, fur-
ther elucidated the molecular basis of retinoid-induced RXR-
dependent trans-activation by Nur77, and provided a tran-
scriptional, biochemical, and structural analysis of coactivator
function and recruitment.
EXPERIMENTAL PROCEDURES
Cell Culture and Transient Transfection—Proliferating C2C12 cells
and COS-1 cells were kept in DMEM supplemented with 20 and 10%
fetal calf serum (FCS), respectively, in 6% CO2. Cells grown in 12-well
dishes to 60–70% confluence were transiently transfected with 0.33–1
g of pGL2b-tk-LUC (37) or pNBRE3-tk-LUC (31–33) reporter plasmid
together with 0.33–0.5 g of pSG5-Nur77FL or pSG5-Nur77AB, or
pSG5-Nur77LBD or pSG5 alone using a DOTAP/DOSPER (Roche
Molecular Biochemicals) liposome mixture in HEBS (42 mM HEPES,
275 mM NaCl, 10 mM KCl, 0.4 mM Na2HPO4, 11 mM dextrose, pH 7.1)
(total DNA 2–2.5 g/well). The DNA/DOTAP/DOSPER mixture was
added to the cells in 1 ml of fresh DMEM containing 10% FCS and
incubated for 14 h. After transfection the medium was replaced, and the
cells were grown a further 24–48 h. Cells were harvested and assayed
for luciferase activity. Each experiment represented at least two sets of
independent triplicates to overcome the variability inherent in trans-
fection experiments (37–42).
Luciferase Assays—Luciferase activity was assayed using a Luclite
kit (Packard) according to the manufacturer’s instructions. Briefly, cells
were washed once in phosphate-buffered saline and resuspended in 150
l of phenol red-free DMEM and 150 l of Luclite substrate buffer. Cell
lysates were transferred to a 96-well plate, and relative luciferase units
were measured for 5 s in a Wallac Trilux 1450 microbeta luminometer.
GAL4 Hybrid Assays—C2C12 and COS-1 cells were passaged into
12-well plates and transfected at 50–80% confluence with 0.33–1 g of
reporter, G5E1b-LUC, and 0.33 g of GAL-Nur77 chimeric constructs
(GAL-Nur77FL, AB, DE, amino acids 1–110, 110–200, 200–269, 1–160,
55–160, and the GAL chimeric constructs containing mutations in the
AB region), or the GAL4 DBD alone in the presence and absence of
vectors pSG5-SRC-2 (0.33–0.66 g) and/or pSG5-RXR (0.66 g) ex-
pression plasmid/well, using a DOTAP/DOSPER liposome mixture in
HEBS. Transfections were performed in DMEM containing 10% FCS or
5% CST (DMEM containing charcoal-stripped FCS was used for trans-
fections performed with GAL constructs cotransfected with pSG5-RXR
in the presence and absence of 1 M 9-cis-RA). After 16–24 h the
medium was replaced, and the cells were harvested 24–48 h after
transfection for the assay of luciferase activity. Each experiment rep-
resented at least two sets of independent triplicates to overcome the
variability inherent in transfection experiments (37–42).
Plasmids and Primer Sequences—The expression plasmids GAL0
(43), pSG5 (Stratagene), pSG5-RXR, and pSG5-RXR-AB (CDE) (42)
and the reporter plasmids pNBRE3-tk-LUC (31–33) and G5E1b-LUC
(44) have been described elsewhere. Generation of full-length mouse
Nur77 was performed by reverse transcription-PCR from muscle RNA
with Pfu DNA polymerase (Promega), using the manufacturer’s buffer.
All PCR products were cloned into the EcoRI site of pSG5 (Stratagene)
and then isolated after EcoRI digestion and subsequently cloned into
pGAL0 and pGEX4T1 (Amersham Biosciences). The primers (GENE-
WORKS Australia) used for the synthesis of full-length mouse Nur77
were GMUQ-713 5-GCG GAA TTC ACC ATG CCC TGT ATT CAA
GCT CAA and GMUQ-714 3-GCG GAA TTC TCA GAA AGA CAA TGT
GTC CAT. We then synthesized additional primers to subclone the DE,
AB, ABC, and CDE regions into pSG5 and GAL0. The primers used for
the DE were GMUQ-715 5-GCG GAA TTC ACC ATG CGG CGG AAC
CGC TGC CAG and GMUQ-714 3. The primers used to synthesize the
AB region were GMUQ-713 5 and GMUQ-716 3-GCG GAA TTC TCA
CTC GCT GCC ACC TGA AGC CCC. The primers used to synthesize
the ABC region were GMUQ-713 5 and GMUQ-717 3-GCG GAA TTC
TCA CAG GCG GAG GAT GAA GAG. The primers used to synthesize
the CDE region were GMUQ-718 5-GCG GAA TTC ACC ATG TGT
GCA GTC TGT GGT GAC and GMUQ-714 3.
We subsequently constructed various subdomains of the AB region
by PCR and cloned these segments into the EcoRI/SalI site of GAL4.
The Nur77AB-aa1–110 was subjected to PCR and cloned into SV40-
GAL0 using primers GMUQ-713 5 and GMUQ-719 3-GCG GTC GAC
TCA CAC CTG GAA GTC CTC. The Nur77AB-aa110–200 region was
subjected to PCR and cloned into SV40-GAL0 using primers GMUQ-
720 5-GCG GAA TTC ACC ATG TAC GGC TGC TAC CCG and
GMUQ-721 3-GCG GTC GAC TCA GCC AGT GGG AGG. The
Nur77AB-aa200–269 region was subjected to PCR and cloned into
SV40-GAL0 using primers GMUQ-722 5-GCG GAA TTC ACC ATG
CCC AGC CCC AGC and GMUQ-723 3-GCG GTC GAC TCA CTC
GCT GCC ACC TGA AGC CCC. The Nur77AB-aa1–160 region was
subjected to PCR and cloned into SV40-GAL0 using primers GMUQ-
713 5 and GMUQ-724 3-GCG GTC GAC TCA AAA TGA GCC GTC
CCA.
The Nur77AB-aa55–160 region was subjected to PCR and cloned into
SV40-GAL0 using primers GMUQ-725 5-GCG GAA TTC ACC ATG
TTC ATG GAC GGG and GMUQ-724 3.
We then synthesized several primers for site-directed mutagenesis
and used the Stratagene QuikChange multisite-directed mutagenesis
kit as per the manufacturer’s instructions to produce GAL4-Nur77AB
chimeras that simultaneously carried double, triple, and quadruple
amino acid mutations. Nur77AB mutant primers were synthesized and
5-phosphorylated by GENEWORKS Australia. The primers made were
S54A/T55A-GMUQ-726 5-CTG CCC AGC TTC GCA GCC TTC ATG
GAC GGG, S54P/T55P-GMUQ-727 5-CTG CCC AGC TTC CCA CCC
TTC ATG GAC GGG, S142A/T145A-GMUQ-728 5-TCA GCC CCC
GCA CCA TCT GCA CCC AAC TTC C, and S142P/T145P-GMUQ-729
5-TCA GCC CCC CCC CCA TCT CCA CCC AAC TTC C.
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GST Pulldowns—GST and GST fusion proteins were expressed in
Escherichia coli (BL21) and purified using glutathione-agarose affinity
chromatography as described previously (37–42). The GST fusion pro-
teins were analyzed on 10% SDS-polyacrylamide gels for integrity and
to normalize the amount of each protein. The Promega TNT-coupled
transcription-translation system was used to produce [35S]methionine-
labeled Nur77 and coactivator proteins that were visualized by SDS-
PAGE. In vitro binding assays were performed with glutathione-agar-
ose beads (Sigma) coated with 500 ng of GST fusion protein and 2–10
l of [35S]methionine-labeled protein in 200 l of binding buffer con-
taining 100 mM NaCl, 20 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5%
Nonidet P-40, 5 g of ethidium bromide, and 100 g of bovine serum
albumin. The reaction was allowed to proceed for 1–2 h at 4 °C with
rocking. The affinity beads were then collected by centrifugation and
washed five times with 1 ml of binding buffer without ethidium bromide
and bovine serum albumin. The beads were resuspended in 20 l of
SDS-PAGE sample buffer and boiled for 5 min. The eluted proteins
were fractionated by SDS-PAGE, and the gel was treated with Amer-
sham Amplify fluor, dried at 70 °C, and autoradiographed.
Molecular Modeling—A model of the Nur77 LBD was constructed
using the program Modeler 6.0 with the RAR LBD as a template. The
resulting model was subject to Ramachandran analysis and further
quality checking with the WhatIf suite of programs (www.cmbi.kun.
nl/swift/whatcheck/). Hydrophobic surface analysis was conducted in
SCULPT 3.0. Initial peptide superimposition was achieved using
SPDBV V3.7, and structures were raytraced with the freeware program
Persistence of Vision:POV-Ray (www.povray.org) and the Macintosh
patch MacmegaPov (users.skynet.be/cgi-bin/formd.cgi). Further analy-
sis of peptide docking using a spherical polar Fourier correlation dock-
ing simulation program was performed using the program HEX
(47–49).
RESULTS
Nur77 Trans-activates Gene Expression in a Cell-specific
Manner—Nur77 is expressed in skeletal muscle tissue and
cells (23, 24, 26, 27). We performed reverse transcription-PCR
experiments using total RNA extracted from C2C12 skeletal
muscle cells to isolate full-length Nur77 cDNA. To verify the
integrity of the cloned NR after full-length sequencing we ex-
amined the ability of Nur77 to trans-activate a Nur77-depend-
ent reporter gene, NBRE3-tk-LUC (NBRE derived from the
monomeric consensus binding site AAAGGTCA). This plasmid
contains three copies of a consensus binding site (AAAGGTCA)
cloned upstream of the heterologous herpes simplex virus thy-
midine kinase promoter (31–33) linked to the luciferase gene.
We transfected both myogenic and non-muscle cell types to
investigate cell-specific aspects of NR4A1 function.
We investigated the ability of full-length Nur77 and Nur77
lacking the AB region (Nur77AB construct, which encodes
amino acids 269–601) to trans-activate NBRE3 in muscle and
non-muscle cells in the absence of agonists. In control studies,
C2C12 myogenic cells and COS-1 cells were transfected with
the control reporter plasmid ptk-LUC (lacking an NBRE, in an
pGL2basic backbone), and Nur77 expression plasmids did not
trans-activate the empty LUC reporter plasmid in either cell
type (Fig. 1, A and B). However, when C2C12 muscle cells and
COS-1 cells were cotransfected with the expression vectors
Nur77, Nur77AB, and the reporter plasmid NBRE3-tk-LUC,
we observed muscle-specific Nur77-dependent trans-activation
of gene expression (Fig. 1, C and D). Moreover, these experi-
ments suggest that the LBD (DE) region of Nur77 is not suffi-
cient to mediate trans-activation of gene expression (Fig. 1C).
In summary, the data suggest that Nur77 trans-activated gene
expression in a cell-specific manner and that efficient trans-
activation requires the AB region, which encodes AF-1.
The AB (AF-1) Region of Nur77 Is Necessary for Agonist-
independent and Nur77-mediated Trans-activation: AF-1
Functions in a Cell-specific Manner—The previous experi-
ments suggested that the Nur77 LBD, unlike other orphan and
classical NRs, could not exclusively facilitate trans-activation
and that Nur77 operated in an AF-1-dependent manner. We
went on to examine the role of the AB region in Nur77-medi-
ated trans-activation from the NBRE3-tk-LUC plasmid. We
investigated and compared the ability of full-length Nur77,
Nur77 lacking the AB region (Nur77AB construct containing
amino acids 269–601), and Nur77 lacking the DE region
(Nur77LBD construct encoding amino acids 1–356) to trans-
activate NBRE in muscle and non-muscle cells in the absence
of agonists. Cell specificity has been found to play an important
role in the activation functions of the AB and DE domains in
the estrogen, glucocorticoid, progesterone, and retinoic acid
receptors (45, 46). The ability of different AFs to function has
been found to (i) vary in relation to the cell line used and (ii)
depend on the spatio-temporal expression pattern of the spe-
cific receptor, indicating that cell-specific activation mecha-
nisms are involved in the functioning of the different AFs.
Nur77 is expressed in skeletal muscle (23, 24, 26, 27). Hence,
we investigated whether the AB region that encodes the AF-1
domain of Nur77 independently activates gene expression in a
cell-specific fashion. C2C12 myogenic cells were cotransfected
with receptor expression vectors Nur77, Nur77LBD, and
Nur77AB, and the reporter plasmid pNBRE-tk-LUC. As ex-
pected, Nur77 trans-activated gene expression 10-fold in
C2C12 cells, and Nur77AB did not activate transcription in
C2C12 or COS-1 cells (Fig. 1, E and F, respectively). Surpris-
ingly, the Nur77LBD construct trans-activated gene expres-
sion 10-fold in a cell-specific manner, as efficiently as the
native receptor.
These experiments indicated that the AB region, which en-
coded the AF-1 domain, was necessary for optimal Nur77-de-
pendent trans-activation of NBRE-dependent reporters in
C2C12 muscle cells. Furthermore, and more importantly, these
experiments clearly demonstrate that the AB region, which
encodes the AF-1 of Nur77, functions in a cell-specific manner
and operates in an AF-2/LBD-independent manner.
The AB Region of Nur77 Encodes a Potent AF-1 Domain
Located between Amino Acid Positions 1 and 160—To identify
and further characterize the domains of Nur77 involved in
transcriptional activation, we utilized the GAL4 hybrid system,
whereby putative activation domains are fused to the DBD of
the yeast transcription factor GAL4 (43). If these regions en-
code modular activation domains, they complement the GAL4
DBD (to produce a functional trans-activator) and induce the
transcription of the GAL-responsive reporter construct G5E1b-
LUC, containing an E1b TATA box with five 17-mer GAL4
binding sites linked to the luciferase gene reporter. The system
utilized an SV40 promoter expression vector pGAL4-DBD (43),
which contains a multiple cloning site downstream of the GAL4
DBD. We fused Nur77 and various domains (e.g. AB or DE
regions) of Nur77 to the GAL4 DBD and examined the ability of
these chimeras to regulate the expression of the G5E1b-LUC
reporter in C2C12 and COS-1 cells. The GAL4-Nur77 chimera
containing the full open reading frame of Nur77 activated
transcription 100-fold above the control, pGAL0 (GAL4 DBD)
in a cell-specific manner (Fig. 2, A and B). The GAL-Nur77AB
plasmid, which contains only the AB regions of Nur77, with the
DBD and LBD deleted, increased transcription of the reporter
construct 200-fold over the GAL DBD alone, in myogenic
cells, and1,000-fold in non-muscle cells (Fig. 2, A and B). This
indicated that the AB region of Nur77 contained a potent
ligand-independent AF-1 domain. Interestingly, in the absence
of its native DBD and LBD, and outside the context of the
native receptor in the GAL4 chimera, the activity of the AF-1
domain was not restricted to muscle.
The GAL-Nur77DE, which encodes the LBD of Nur77 with
the AB and C regions deleted, did not activate transcription
(Fig. 2, A and B), which was consistent with the reporter
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analysis. This suggested that the LBD lacked an intrinsic and
classical transcriptional domain.
The AB region is comprised of 269 amino acids, which en-
codes a potent N-terminal AF-1 domain. To characterize fur-
ther the AF-1 region of Nur77, we have constructed subregions
of the AB domain by PCR and cloned these segments into the
GAL4 DBD (Fig. 3A). These constructs were transfected into
COS-1 cells and assayed in the GAL4 hybrid system (Fig. 3A).
The constructs GAL-Nur77-aa1–110, GAL-Nur77-aa110–200,
and GAL-Nur77-aa200–269 were created and assayed by
transfection. These segments of the AB region of Nur77 in-
creased activation 75-, 16-, and 2-fold relative to the control,
GAL DBD, alone. This suggested the AF-1 domain was located
between amino acid positions 1 and 200 in the AB region. The
plasmid, GAL-Nur77-aa200–269, did not trans-activate gene
expression in this assay system. These data demonstrated that
amino acids 200–269 were not essential for the activity of the
AF-1 domain and did not contain an activation function. We
subsequently constructed GAL-Nur77-aa1–160 and GAL-
Nur77-aa55–160 and assayed these plasmids by transfection
analysis. These segments of the AB region of Nur77 increased
activation 280- and 44-fold relative to the GAL4 DBD alone.
This delimited the AF-1 domain to between amino acid posi-
tions 1 and 160 in the AB region and showed that the region
downstream of position 160 was not essential for the activity of
the AB region.
This delimited domain has two S/T-rich areas between amino
acids 50 and 60 and amino acids 140–150 which are highly
conserved among the three members of the NR4A subgroup
(Nur77, Nurr1, and NOR-1), and cross species (i.e. mouse and
human). Moreover, phosphorylation of Ser-142 has been impli-
cated in the nucleo-cytoplasmic shuttling of Nur77 (7). Conse-
quently, we investigated whether these regions played a role in
AF-1 activity. This was investigated by site-specific mutagen-
esis of Ser-54, Thr-55, Ser-142, and Thr-145 within the AF-1
domain of Nur77. The AB region carrying various combinations
of mutants was cloned into the GAL4 hybrid system. We con-
structed several mutants that carry multiple mutations, GAL4-
AB-S54P/T55P, GAL4-AB-S142A/T145A, GAL4-AB-S54A/
T55A/T145A, and GAL4-AB-S54A/T55A/S142A/T145A. We
FIG. 1. A–D, Nur77 trans-activates gene expression in a cell-specific manner. 0.33 g of SG5-Nur77FL and SG5-Nur77AB was cotransfected
into C2C12 proliferating myoblasts and COS-1 cells together with 1 g of the reporter genes pGL2b-tk-LUC (A and B) or NBRE3-tk-LUC (C and
D). E and F, the AB (AF-1) region of Nur77 is necessary for agonist-independent and Nur77-mediated trans-activation of gene expression. AF-1
functions in a cell-specific manner. 0.33 g of SG5-Nur77FL, SG5-Nur77LBD, and SG5-Nur77AB was cotransfected into C2C12 proliferating
myoblasts (E) and COS-1 cells (F) together with 1 g of the reporter gene NBRE3-tk-LUC. -Fold activation is expressed relative to luciferase
activity obtained after cotransfection of the pSG5 alone, arbitrarily set at 1. The mean luciferase -fold activation values  S.D. (bars) were derived
from a minimum of two or three independent triplicate experiments.
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observed that these mutations had minimal effect on the activ-
ity of the AB region in COS-1 cells (data not shown) and C2C12
cells (Fig. 3B). However, we observed that simultaneous muta-
tion of Ser-142 and Thr-145 moderately increased the activity
of the AF-1.
SRC-2 Stimulates the Activity of the Nur77 AF-1 Domain but
Not the Putative LBD—The process of cofactor recruitment and
the interaction of coactivators with the NR4A subgroup have
remained obscure and have not been described to date. Because
Nur77 can activate transcription directly and/or by tethered
protein-protein interactions with RXR (31–33), we examined
the effect of SRC-2 (GRIP-1) expression on Nur77-mediated
trans-activation in the GAL4 hybrid system (Fig. 4). In these
assays the activity of Nur77 is independent of its binding to its
cognate binding motif, the NBRE. If SRC-2 regulates the tran-
scriptional activity, then the potential of the GAL4-Nur77 fu-
sions to trans-activate gene expression should be increased in
this assay (Fig. 4, A and B).
Cells were cotransfected with GAL-Nur77AB, GAL-
Nur77DE, GAL-Nur77-aa110–200, and GAL-Nur77-aa55–160,
and the G5E1b-LUC reporter, in the presence and absence of
an SRC-2 expression vector. G5E1b-LUC contains five copies of
the GAL4 binding site placed upstream of a minimal E1b
promoter.
As expected, transfection of GAL-Nur77AB and GAL-Nur77-
aa55–160 efficiently induced transcription relative to the GAL4
DBD, and this level of activity was stimulated significantly by
4-fold by the addition of SRC-2. Moreover, GAL-Nur77-aa110–
200 was stimulated  10-fold by coexpression of SRC-2. This
suggested that SRC-2 modulates the activity of the N-terminal
AF-1 domain in Nur77, and this coactivation is dependent on
the region between amino acid positions 110 and 160 in the AB
region. SRC-2 did not modulate or increase the activity of the
C-terminal LBD (Fig. 4B).
FIG. 2. A and B, the AB region of Nur77 encodes a potent AF-1
activation domain. 0.33 g of GAL-Nur77FL, GAL-Nur77AB, and GAL-
Nur77DE was cotransfected with 1 g of the GAL reporter G5E1b-LUC
into C2C12 proliferating myoblasts (A) and into COS-1 cells (B). -Fold
activation is expressed relative to luciferase activity obtained after
cotransfection of the GAL4 DBD alone, arbitrarily set at 1. The mean
luciferase -fold activation values  S.D. (bars) were derived from a
minimum of two or three independent triplicate experiments.
FIG. 3. A, the activation domain within the AB region is located
between amino acid positions 1 and 160. 0.33 g of GAL-Nur77AB,
GAL-Nur77-aa1–110, GAL-Nur77-aa110–200, GAL-Nur77-aa200–
269, GAL-Nur77-aa1–160, and GAL-Nur77-aa55–160 chimeras was co-
transfected with 1 g of the GAL4-dependent reporter G5E1B-LUC into
COS-1 cells. B, 0.33 g of GAL-Nur77AB, GAL4-AB-S54P/T55P, GAL4-
AB-S142A/T145A, GAL4-AB-S54A/T55A/T145A, and GAL4-AB-S45A/
T55A/S142A/T145A (GAL4-Nur77AB chimeras that carried double, tri-
ple, and quadruple amino acid mutations, respectively) were
cotransfected with 1 g of the GAL4-dependent reporter G5E1B-LUC
into C2C12 cells. -Fold activation is expressed relative to luciferase
activity obtained after cotransfection of the GAL4 DBD alone, arbi-
trarily set at 1. The mean luciferase -fold activation values S.D. (bars)
were derived from a minimum of two or three independent triplicate
experiments.
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SRC-2 Potentiates the Retinoid-induced RXR-dependent Ac-
tivation of the Nur77 LBD—The NR4A family members can
bind as monomers and as homodimers to single/tandem copies
of the NBRE, a variant NR half-site, and constitutively regu-
late transcription (28–30). Moreover, Nur77 and Nurr1 (but
not NOR-1) heterodimerize with the C-terminal RXR LBD and
mediate efficient trans-activation in response to RXR-specific
agonists from a DR5 motif (GGTTCA n5 AGTTCA) (31–33). The
Nur77 LBD lacks an intrinsic activation domain; however,
mutations and deletions in the AF-2 domain affect ligand-
independent function (32, 33, 36, 50). Moreover, this receptor
subgroup has proved refractory to the understanding of coac-
tivator recruitment in the process of trans-activation (50).
Consequently, we examined the ability of SRC-2 to modulate
the activity of the GAL4-Nur77 chimeras in the presence and
absence of RXR (which is preferentially expressed in skeletal
and cardiac muscle) (42) and the RXR agonist 9-cis-RA (Fig.
5A). Cells were cotransfected with GAL-Nur77DE, SRC-2, and
RXR expression vectors, in the presence and absence of 9-cis-
RA. As expected, cotransfection of RXR in the presence of
9-cis-RA increased the activity of the Nur77DE 100-fold rel-
ative to the control GAL4 DBD alone (Fig. 5, B and C). Coex-
pression of SRC-2 potently and dramatically potentiated the
retinoid-induced RXR-dependent activity of the Nur77 LBD
from 73-fold (relative to the GAL4 DBD alone) to a dramatic
2,610-fold (relative to the GAL4 DBD), which translates to a
35-fold increase in the activity of the Nur77 LBD (Fig. 5B). In
contrast, the activity of the GAL4 DBD alone was increased
6-fold by retinoids in similar conditions (i.e. in the presence of
RXR and SRC-2) (Fig. 5C). This demonstrated that SRC-2
(GRIP-1) coactivates the efficient Nur77-mediated retinoid-in-
duced RXR-dependent trans-activation.
The Steroid Receptor Coactivators Interact Directly with
Nur77: The AF-1 Domain Recruits SRC—The N-terminal AF-1
FIG. 4. SRC-2 potentiates the activity of the Nur77AB region.
A, a diagrammatic representation of the GAL4 hybrid assay is shown.
This assay was used to determine the effect of SRC-2 (GRIP-1) expres-
sion on Nur77-mediated trans-activation of gene expression. B, 0.33 g
of GAL-Nur77AB, GAL-Nur77DE, GAL-Nur77-aa110–200, and GAL-
Nur77-aa55–160 was cotransfected with 1 g of the GAL4-dependent
reporter G5E1B-LUC into COS-1 cells in the presence and absence of
0.66 g of the cotransfected expression plasmid encoding SG5-SRC-2.
-Fold activation is expressed relative to luciferase activity obtained
after cotransfection of the GAL4 DBD alone, arbitrarily set at 1. The
mean luciferase -fold activation values  S.D. (bars) were derived from
a minimum of two or three independent triplicate experiments.
FIG. 5. SRC-2 stimulates the retinoid-induced RXR-dependent
activation of the Nur77 LBD. A, a diagrammatic representation of
the GAL4 hybrid assay is shown. This assay was used to determine the
effect of SRC-2 (GRIP-1) expression on retinoid-induced RXR-depend-
ent activation of the Nur77 LBD. COS-1 cells were cotransfected with
0.33 g of GAL-Nur77DE (B) or GAL4 DBD (C), 0.33 g of SG5-SRC-2,
and 0.66 g of SG5-RXRAB together with 1 g of the GAL4-depend-
ent reporter G5E1B-LUC in the presence and absence of 1 M 9-cis-RA.
-Fold activation is expressed relative to luciferase activity obtained
after cotransfection of the GAL4 DBD alone, arbitrarily set at 1. The
mean luciferase -fold activation values  S.D. (bars) were derived from
a minimum of two or three independent triplicate experiments.
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region, the C-terminal LBD (and the imbedded AF-2 domain) of
the NR4A subgroup, is very unusual and has not been demon-
strated to interact directly with coactivators. However, we have
demonstrated that SRC-2 modulates the activity of the Nur77
AF-1 domain. Furthermore, activation of gene expression by
the classical nuclear hormone receptors is linked to recruit-
ment of SRC-1, -2, and -3. These SRCs recruit p300/CREB-
binding protein and PCAF to activate transcription synergisti-
cally. SRCs, CREB-binding protein/p300, and PCAF possess
intrinsic histone acetyltransferase activity and act in concert to
remodel the chromatin. This complex results in the assembly of
a higher order structure that includes the DRIPTRAPARC
protein complex that regulates localized nucleosome structure
(for review, see Ref. 51).
Consequently, we examined the ability of the SRCs (-1, -2,
and -3) to interact directly with Nur77. We tested this hypoth-
esis using a biochemical approach, the in vitro GST pulldown
assay. Glutathione-agarose-immobilized GST-Nur77, GST-
Nur77AB, and GST-Nur77DE were tested for direct interaction
with in vitro 35S-radiolabeled full-length SRC-1, -2, and -3 (Fig.
6A). We observed that SRC-1 and -2 interacted efficiently with
Nur77. Surprisingly, SRC-1 and -2 interacted directly with the
AB region of Nur77, which encoded the potent AF-1 domain. In
contrast to other nuclear hormone receptors the DE region that
encodes the LBD did not interact with the steroid receptor
coactivators (Fig. 6A). This is consistent with the NBRE re-
porter assays and the GAL4 hybrid analysis.
p300 and PCAF Interact Directly with the N-terminal AF-1
Domain: the AB Region Mediates Directs Coactivator Recruit-
ment—To investigate cofactor recruitment further, we exam-
ined the ability of p300 and PCAF to interact with Nur77.
Glutathione-agarose-immobilized GST-Nur77, GST-Nur77AB,
and GST-Nur77DE were tested for direct interaction with in
vitro 35S-radiolabeled full-length p300 and PCAF. We observed
that p300 and PCAF interacted efficiently with Nur77 and
Nur77AB (Fig. 6B). Surprisingly, p300 interacted very poorly
with the C-terminal LBD of Nur77 (Fig. 6B). We also investi-
gated the interaction of DRIP-205 with Nur77; however, we did
not observe any significant binding (Fig. 6C).
As described, SRC, p300, and PCAF interacted independ-
ently and directly with GST-Nur77 and GST-Nur77AB. How-
ever, we also observed that GST-Nur77 and GST-Nur77AB
could simultaneously and efficiently pull down SRC, p300, and
PCAF (Fig. 6D). In contrast, the DE region that encodes the
LBD interacted poorly with this complex. Moreover, we dem-
onstrated that in the presence of SRC-2 and p300, Nur77
and the Nur77 AF-1 interacted significantly with DRIP-205
(Fig. 6E).
These studies suggested that the AB region that encodes the
AF-1 domain mediates cofactor recruitment in Nur77 and that
the LBD interacts poorly with coactivators.
The Nur77 LBD Coactivator Binding Cleft Is Unusually Hy-
drophilic: Coactivator-derived Peptide Binds Poorly in Docking
Simulations—We used molecular modeling as a tool to inves-
tigate further the inability of the atypical NR LBD to interact
with coactivators. The starting point for homology modeling
was the crystal structure of the human RAR in a complex with
the retinoid Cd564 (PDB number 1FCY). Alignments were
performed with ClustalV and adjusted manually thereafter.
Homology modeling was performed by satisfaction of spatial
restraints using the program Modeler6 (47). The resulting
model was subjected to Ramachandran analysis and further
quality checking with the WhatIf suite of programs. Hydropho-
bicity analysis was performed using the molecular modeling
program SCULPT (48). An LXXLL-containing peptide from a
previously published thyroid hormone receptor-steroid receptor
coactivator peptide complex was superimposed onto both the
RAR and Nur77 LBDs, enabling us to delineate a hypothetical
coactivator binding interface.
Fig. 7 shows ribbon and surface views of the template struc-
ture from human RAR (A), and the modeled Nur77 (B). Exam-
ination of the molecular surface in the region of the hypothet-
ical coactivator interfaces shows startling differences in
hydrophobicity; human RAR (C) shows the characteristic hy-
drophobic groove (blue) found in AF-2 activating receptors,
whereas Nur77 (D) encoded an unusually hydrophilic surface
(red shade). Additionally, there are conspicuous changes in
local surface topography as shown in close-up views (E and F).
This prompted us to use the spherical polar Fourier correlation
docking simulation program HEX (49) to assess the ability of
the Nur77 LBD to bind a coactivator-derived peptide (E and F).
When we performed this simulation using the LBD of RAR we
found that 6 of the 10 highest scoring solutions docked to
FIG. 6. A, SRCs interact directly with the Nur77 AF-1 domain. Glu-
tathione-agarose-immobilized GST, GST-Nur77, GST-Nur77AB, and
GST-Nur77DE were incubated independently with in vitro 35S-radiola-
beled full-length SRC-1, SRC-2, and SRC-3. The input lane represents
10% of the total protein. B, p300 and PCAF interact directly with the
Nur77 AF-1 domain. GST, GST-Nur77FL, GST-Nur77AB, and GST-
Nur77DE were incubated independently with in vitro 35S-radiolabeled
full-length p300 and PCAF. The input lane represents10% of the total
protein. C, GST and GST-Nur77AB were incubated independently with
in vitro 35S-radiolabeled full-length SRC-2, DRIP-205, and p300. The
input lane represents 10% of the total protein. D, GST, GST-Nur77,
GST-Nur77AB, and GST-Nur77DE were incubated simultaneously
with in vitro 35S-radiolabeled full-length p300, SRC-2, and PCAF. The
input lane represents 10% of the total protein. E, GST, GST-
Nur77AB, and GST-Nur77 were incubated simultaneously with in vitro
35S-radiolabeled full-length SRC-2, DRIP-205, and p300. The input lane
represents 5% of the total protein.
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within 2 Å root mean square of a coactivator/receptor model
based on superposition of the existing thyroid hormone recep-
tor-SRC-2 (GRIP-1) peptide crystal structure. In contrast, the
best 100 solutions for Nur77 did not approach to within 5 Å of
the equivalent position (data not shown). This is most likely
because of the differences in hydrophobicity and topology be-
tween the two interfaces. Given the dominance of the SRC-2
(GRIP-1) type LXXLL coactivator peptide in receptor interac-
tion, this observation may account for the inability of this NR
LBD to mediate cofactor recruitment directly.
The N-terminal AB Region Interacts Directly with the C-
terminal LBD: the Interaction Is Potentiated by AF-1-mediated
Recruitment of SRC—It has been demonstrated previously that
human SRC-2 concomitantly interacts with the estrogen recep-
tor AF-1 and AF-2 to regulate transcription synergistically
(52–54). Our studies suggested that the Nur77 AF-1, but not
the C-terminal LBD, interacts with SRC. We investigated
whether the atypical role of the Nur77 LBD in transcriptional
activation involved intramolecular interactions with the N-
terminal AF-1 and whether this process was modulated by SRC
recruitment (Fig. 8A).
We tested this hypothesis using a biochemical approach, the
in vitro GST pulldown assay. Glutathione-agarose-immobilized
GST-Nur77AB was tested for direct interaction with in vitro
35S-radiolabeled full-length SRC-2 and the Nur77 LBD (CDE)
(Fig. 8A). As expected from our studies above we observed that
SRC-2 interacted efficiently with the Nur77AB. Very interest-
ingly, we observed that the N-terminal AB region that encodes
the potent AF-1 domain interacts directly with the C-terminal
LBD region. Furthermore, the interaction is potentiated signif-
icantly by AF-1-mediated recruitment of SRC (Fig. 8B). This
evidence clearly demonstrates intramolecular interactions be-
tween the N-and C-terminal regions of the Nur77 and provides
evidence for the involvement of the Nur77 LBD in the absence
of an intrinsic activation function. In summary this suggests
that SRC-2 potentiates the direct interaction between the N-
terminal AF-1 domain and the C-terminal LBD region of
Nur77.
The Nur77 AF-1 Domain Synergizes with the RXR LBD in a
Retinoid-dependent Manner—In the context of the above data
we hypothesized that the Nur77 AF-1 may mediate transcrip-
tional synergy with RXR during retinoid-induced RXR-depend-
ent activation of Nur77 (Fig. 9A). Consequently, we examined
the ability of RXR to potentiate the activity of the GAL4-
Nur77 AB plasmid (which encodes AF-1) in the presence and
absence of the RXR agonist, 9-cis-RA. The experiments were
controlled internally with the GAL4 DBD, and GAL4-
Nur77DE, which has been well characterized in the literature
and in this study with respect to retinoid-induced RXR-specific
modulation.
9-cis-RA increased the activity of the GAL-Nur77DE chimera
in the presence of RXR approximately 728-fold (Fig. 9B). In
contrast, the activity of the GAL4 DBD alone was increased
4-fold by 9-cis-RA in similar conditions (i.e. in the presence of
RXRAB) (Fig. 9C).
FIG. 7. Molecular modeling of the Nur77 LBD: comparison of
the RAR LBD with the LBD of Nur77. RAR from crystal structure
1FCY (A) and the Nur77 (B) LBD model and are shown in ribbon form.
Helices 3–5 (signature motif) are highlighted in red, and helix 12 is
colored blue. An LXXLL peptide (colored pink) from a previously pub-
lished thyroid hormone receptor-SRC-2 (GRIP-1) coactivator complex
has been superimposed on both structures to delineate a hypothetical
coactivator interaction interface. Critical leucines within the coactiva-
tor peptide are depicted in stick form. The backbone conformations of
the two LBDs are very similar. C and D, hydrophobic analysis of RAR
(C) and Nur77 (D) molecular surfaces. Surfaces were defined by a probe
with a radius of 1.4 Å using SCULPT 3.0. Hydrophobic areas are colored
blue, and hydrophilic areas are colored red. SRC-2 (GRIP-1) coactivator
peptide from a previously published structure (55) has been superim-
posed to delineate an approximate coactivator binding area. Leucines
from the coactivator peptide are depicted in stick form. A reduction in
hydrophobicity is apparent in the Nur77 LBD (D) coactivator interface
region compared with a similar area of RAR (C). Additionally, the
surface topography is different in this region despite the similarity in
backbone conformation. E and F, close-up views of hydrophobic analysis
focusing on interaction of leucines from the coactivator peptide with the
RAR (E) and Nur77 LBD surfaces (F).
FIG. 8. AF-1 domain interacts directly with the LBD of Nur77.
This interaction is potentiated by AF-1-mediated recruitment of SRC-2.
A, diagrammatic representation of the intramolecular interaction be-
tween AF-1 and AF-2 of Nur77 which is potentiated by AF-1-mediated
recruitment of SRC-2. B, GST (third and fourth lanes) and GST-
Nur77AB (sixth and seventh lanes) were incubated independently with
in vitro 35S-radiolabeled SRC-2 and Nur77CDE, respectively. GST (fifth
lane) and GST-Nur77AB (eighth lane) were incubated simultaneously
with in vitro 35S-radiolabeled SRC-2 and Nur77CDE.
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9-cis-RA increased the activity of the GAL-Nur77AB chimera
in the presence of RXR 13-fold (Fig. 9D). The GAL4 DBD
alone was increased 4-fold by 9-cis-RA in similar conditions
(i.e. in the presence of RXRAB) (Fig. 9C). This suggested that
the Nur77 AF-1 synergizes very efficiently with RXR. We
observed stimulation of the Nur77 AF-1 by 9-cis-RA in the
absence of exogenous RXR, which reflects the well character-
ized low endogenous expression of RXRs in this cell type
(56, 57).
We verified the interaction of the Nur77 AF-1 with RXR
using a biochemical approach, the in vitro GST pulldown assay.
Glutathione-agarose-immobilized GST-Nur77AB was tested
for direct interaction with in vitro 35S-radiolabeled SRC-2 (as a
control) and RXR (Fig. 9E). As expected from our previous
experiments, we observed that SRC-2 interacted efficiently
with the Nur77AB. Moreover, we observed that the N-terminal
AB region that encodes the potent AF-1 domain interacts di-
rectly withRXR (Fig. 9E) and is in agreement with the GAL4
analysis.
DISCUSSION
In this investigation we have provided compelling evidence
that Nur77-mediated trans-activation operated in an AF-1-de-
pendent manner. The AB region encodes an uncommonly po-
tent N-terminal AF-1 domain delimited to between amino acids
50 and 160, which is essential for the ligand-independent acti-
vation of gene expression. Interestingly, the N-terminal AB
region (not the LBD) facilitates coactivator recruitment; inter-
acts directly with SRC, p300, PCAF, and DRIP-205; and syn-
ergizes with RXR in a retinoid-dependent manner. Moreover,
we demonstrate that SRC-2 (GRIP-1) (i) modulates the agonist-
independent activity of the N-terminal AF-1 domain; (ii) poten-
tiates the retinoid-induced RXR-dependent activation of the
Nur77 LBD; and (iii) facilitates the physical association of the
N-terminal AF-1 with the C-terminal LBD of Nur77. The re-
sults imply that the AF-1 domain plays a major role in Nur77-
mediated transcriptional activation, cofactor recruitment, and
intra- and intermolecular interactions.
Activation by nuclear hormone receptors is mediated by two
distinct regions localized within the N- and C-terminal AF-1
and AF-2 regions, respectively. The AF-1 domain is structur-
ally divergent, the AF-2 region is evolutionary conserved, sug-
gesting a general mechanism for transcriptional regulation (1).
Accordingly, the majority of receptors regulate gene expression
and recruit coactivator complexes in a C-terminal AF-2-de-
pendent manner (51). However, the rat Nur77 LBD (i.e.
NGFI-B) does not encode an activation domain per se. More-
over, the N-terminal of NGFI-B encodes a domain important
for transcriptional activity, and this receptor subgroup has
FIG. 9. AF-1 domain of Nur77 synergizes with RXR LBD in a retinoid-dependent manner. A, diagrammatic representation of the GAL4
hybrid assay. This assay was used to determine the effect of retinoid-induced RXR-dependent activation of the Nur77 AB region. B, COS-1 cells
were cotransfected with 0.33 g of GAL4-Nur77DE and 0.66 g of SG5-RXRAB together with 1 g of the GAL4-dependent reporter G5E1B-LUC
in the presence and absence of 1 M 9-cis-RA. C, COS-1 cells were cotransfected with 0.33 g of GAL4 DBD and 0.66 g of SG5-RXRAB together
with 1 g of the GAL4-dependent reporter G5E1B-LUC in the presence and absence of 1 M 9-cis-RA. D, COS-1 cells were cotransfected with 0.33
g of GAL-Nur77AB and 0.66 g of SG5-RXRAB together with 1 g of the GAL4-dependent reporter G5E1B-LUC in the presence and absence
1 M 9-cis-RA. -Fold activation is expressed relative to luciferase activity obtained after cotransfection of the GAL4 DBD alone, arbitrarily set at
1. The mean luciferase -fold activation values  S.D. (bars) were derived from a minimum of two or three independent triplicate experiments. E,
GST (third and fourth lanes) and GST-Nur77AB (fifth and sixth lanes) were incubated independently with in vitro 35S-radiolabeled SRC-2 and
RXR, respectively.
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proved refractory to the elucidation of coactivator recruitment
(36, 50).
Specifically, in this study we demonstrate that Nur77
(mouse NR4A1) trans-activates gene expression in a cell-spe-
cific manner and in an AF-1-dependent manner. This is con-
sistent with the cell-specific gene expression of NR4A2/Nurr1,
and the spatio-temporal specific patterns of expression associ-
ated with this gene family (33, 50). This suggests that Nur77
activity is dependent on a cell-specific signal transduction
pathway and/or combination of cofactors.
The Nur77 N-terminal AB region encodes an unusually po-
tent AF-1 domain located between amino acids 1 and 160 and
is modulated by SRC-2 (GRIP-1). Coactivation by SRC-2 is
dependent on the region between amino acids 110 and 160.
The N-terminal AF-1 region, the C-terminal LBD (and the
imbedded AF-2 domain) of the NR4A subgroup, as discussed
has not been demonstrated to interact directly with coactiva-
tors. However, we observed that SRC-2 modulates the activity
of the Nur77 AF-1 domain. Because the activation of gene
expression by the classical nuclear hormone receptors is linked
to the binding of SRCs and the subsequent recruitment of
p300/CREB-binding protein and PCAF (51), we investigated
coactivator interactions with the GST pulldown assay. We ob-
served that the SRCs, p300 and PCAF interacted directly with
the AB region of Nur77 which encoded the potent AF-1 domain.
In contrast to other NRs, the DE region that encodes the LBD
did not interact with the coactivators, SRC-1, -2, and p300. This
is consistent with the NBRE reporter assays and the GAL4
hybrid analysis, which suggested the Nur77 LBD did not con-
tain an intrinsic activation domain. This demonstrated that the
N-terminal AB region mediates coactivator recruitment in
Nur77 and explains the atypical nature of NR4A-mediated
trans-activation. Furthermore, in a cofactor-dependent man-
ner, the AB region of Nur77 and not the LBD interacted with
DRIP-205, which is involved in the regulation of nucleosome
structure.
Interestingly, we show that the AF-1-mediated recruitment
of SRC-2 promotes intramolecular interactions with the LBD
which may function to stabilize the receptor during agonist-
independent transcription.
Serine/threonine-rich domains in the N terminus have been
implicated in the regulation of NGFI-B-dependent transcrip-
tion (7, 35, 36). Furthermore, the N terminus and phosphoryl-
ation of amino acid residues in the AB region are required for
the growth factor-dependent nucleo-cytoplasmic shuttling and
regulation by extracellular signal-regulated kinase-2, Trk, Ras,
and mitogen-activated protein kinase (7, 35, 36). We mutated
the serine and threonine residues at amino acid positions 54,
55, 142, and 145, which had previously been implicated as key
kinase targets during growth factor-dependent modulation (7,
35, 36). However, these residues were not involved in the
transcriptional modulation of this NR in our cell culture sys-
tems, and the literature suggests that phosphorylation of these
residues mediates nucleo-cytoplasmic transport of this orphan
receptor (see below). We did consistently observe a modest
increase in the activity of the AF-1 domain when Ser-142 and
Thr-145 were mutated simultaneously.
NGFI-B (rat Nur77) and Nurr1 (but not NOR-1) het-
erodimerize with the C-terminal RXR LBD and mediate effi-
cient trans-activation in response to RXR-specific agonists (31–
33). Our study demonstrated that SRC-2 (GRIP-1) potently
coactivates the retinoid-induced RXR-dependent trans-activa-
tion of Nur77-mediated transcription. Moreover, we provided
evidence for transcriptional synergy between the Nur77 AF-1
and the RXR LBD in a 9-cis-RA-dependent manner. These
intermolecular interactions mediated by the Nur77 AF-1 with
the LBD of RXR are consistent with the observations that
growth factor-dependent phosphorylation of the N-terminal AB
region of Nur77 regulates nucleo-cytoplasmic translocation of
this NR and the modulation of retinoid signaling (7).
Our molecular modeling analysis of the NR4A1 (Nur77) C-
terminal DE region structurally substantiates the inability of
this orphan LBD to interact with coactivators (e.g. SRC-2
(GRIP-1)). Examination of the molecular surface in this regions
shows an unusually hydrophilic surface that is, in contrast to
the archetypal and characteristic hydrophobic groove found in
AF-2-activating receptors (e.g. RAR and thyroid hormone re-
ceptor). Computer modeling strongly suggests that the Nur77
LBD is unable to bind a coactivator-derived peptide because of
the differences in hydrophobicity and topology between the
Nur77 and classical NRs.
These observations are also consistent with the observation
that the AF-2 core regions in the ligand-dependent receptors
(e.g. RAR and RXR) contain a very highly conserved glutamic
acid. This glutamic acid is important for cofactor recruitment
and transcriptional activation (50). In contrast the NR4A sub-
group (Nur77, Nurr1, and NOR-1) have a conserved lysine.
In summary, we have characterized the functional role of
AF-1 in mouse NR4A1 (Nur77)-mediated trans-activation; fur-
ther elucidated the molecular basis of retinoid-induced RXR-
dependent trans-activation by Nur77; and provided a tran-
scriptional, biochemical, and structural analysis of coactivator
function and recruitment.
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